TheEdgeResearch
Home / Stocks / REUN

Reunion Neuroscience Inc. (REUN)

NASDAQ Healthcare Biotechnology
$1.12 ▼ -0.89%
Market Cap
$13.1M
Sector
Healthcare
Industry
Biotechnology
Beta
4.20
52-Wk Range
0.63-21.556
CEO
Gregory T. Mayes
Country
CA
Currency
USD

Reunion Neuroscience Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $1.12, down 0.89% on the session, giving a market capitalisation of $13.1M. On trailing twelve-month figures it carries a trailing P/E of -0.27, a net margin of 0.0%. Its beta of 4.20 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.27
Price / Sales
0.00
Price / Book
0.85
EV / EBITDA
0.32
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
0.16
Current ratio
3.52
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
16
IPO date
2020-10-07
Headquarters
Toronto, ON, CA
About Reunion Neuroscience Inc.

Field Trip Health Ltd. is a North American company specializing in the development and delivery of psychedelic-assisted therapies. The organization operates Field Trip Health Centres, which offer psychedelic-based treatments, and provides digital applications under the Field Trip brand. Additionally, its Field Trip Discovery division focuses on researching and creating next-generation psychedelic molecules. The company also administers ketamine-assisted therapy to address various conditions, including depression, anxiety, and addiction. Established in 2008, Field Trip Health Ltd. is based in Toronto, Canada.

Comparable companies

Reunion Neuroscience Inc. is most often compared with the following Healthcare names:

AXLACYADFTRPGLSHURAIMNNKANTBLSCPXSQZB
More research on REUN
REUN technical analysis REUN TheEdge Score Compare against peers
Open full interactive analysis & DCF →